Shots:
- Biocon has reported the commercial launch of Yesafili, a biosimilar version of Eylea 2mg (aflibercept), in the US, which was previously approved & granted interchangeable designation
- In the P-III (INSIGHT) study in Diabetic Macular Edema (DME), Yesafili showed no clinically meaningful differences from Eylea in PK, safety, efficacy, or immunogenicity
- Yesafili is a VEGF inhibitor approved for the treatment of Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, DME, & diabetic retinopathy
Ref: Businesswire | Image: Biocon | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
